Does omalizumab really benefit patients with severe asthma?, asks DTB

Omalizumab is an injectable treatment for people with severe, allergic asthma that is not controlled by standard therapies. But a lack of evidence to support use of the drug in this group of patients does not justify its high cost, says Drug and Therapeutics Bulletin (DTB) in its review this month.

Dr Ike Iheanacho, editor of DTB comments: “The annual cost of omalizumab ranges from around £3,000 to £20,000 excluding the cost of a healthcare professional preparing and giving the injections.

However, in the key published study that has assessed its effectiveness in patients with severe asthma, omalizumab provided, at best, only a marginal reduction in the rate of asthma exacerbations. There is simply not enough evidence to justify omalizumab’s hype as a wonder drug.”

DTB believes that omalizumab should only be used in the context of clinical trials that aim to provide information on its efficacy in preventing exacerbations, hospital admissions and oral corticosteroid use, as well as its cost-effectiveness.

Also in DTB this month:

When and how it is best to give combination therapy for early rheumatoid arthritis?

  • Around one per cent of adults in the UK have rheumatoid arthritis.
  • Early intervention can reduce long-term joint damage so, patients need to be seen early (preferably within 3 months of first being seen) by a rheumatologist for initiation of disease-modifying-anti-rheumatic drugs (DMARDs).
  • DTB looks at the use of DMARDs to assess whether they should be administered as sole therapy or in combination.  It also looks at when and how best to give combination therapy.

Contact Vicky Taylor on 0207 770 7567 /

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins


Already registered?

Sign in

Follow Us:

Just published

The original Moderna COVID-19 vaccine

First COVID-19 vaccine to target Omicron variant approved for use in UK

The MHRA has approved an updated version of the Moderna vaccine that targets both...

Ballot box

Majority of GPs back taking industrial action in the coming year, poll suggests

The majority of GPs support taking industrial action in the coming 12 months to push...

RCGP sign

NHS winter plan does not provide enough support for GPs, warns RCGP

NHS England's winter plan does not include enough measures to support general practice...

NHS sign

Plans to recruit 1,000 new link workers to support GP practices this winter

NHS England has set out plans to recruit an additional 1,000 social prescribing link...

BMA House

BMA prepares to ballot junior doctors on industrial action

Junior doctors will be balloted over industrial action if the government does not...

Typing on a laptop

NHS 111 systems could be offline until next week following cyber attack

NHS 111 systems could be offline until next week following the cyber attack on a...